Current Report Filing (8-k)
January 02 2020 - 4:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported):
January 2, 2020
___________________________________________________________
ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as specified in
its Charter)
___________________________________________________________
New York
|
1-10113
|
11-0853640
|
(State or other jurisdiction of
|
(Commission File Number)
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Identification Number)
|
616 N. North Court, Suite 120
Palatine, Illinois 60067
(Address of principal executive offices)
(Zip code)
(847) 705-7709
(Registrant’s telephone number, including
area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
Common Stock, $0.01 par value per share
|
ACUR
|
OTC – PINK
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 – Other Events
On January 2, 2020 Acura Pharmaceuticals,
Inc. issued a press release providing an update on the development of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets
using Acura’s LIMITx™ technology intended to mitigate risks associated with overdose of the hydrocodone. A copy of
the press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release of Acura Pharmaceuticals, Inc. dated January 2, 2020
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: January 2, 2020
|
ACURA PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Peter A. Clemens
|
|
Peter A. Clemens
|
|
Senior Vice President & Chief Financial Officer
|
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Historical Stock Chart
From Apr 2023 to Apr 2024